Veritas Intercontinental Closes €5 million of New Financing | Amadeus

Madrid, September 30, 2020 – Veritas Intercontinental, a leader in the application of preventive genomic medicine, has completed a new financing of €5 million that strengthens its international expansion and the development of new operational and technological capabilities. “The renewed support from Charme and Amadeus, together with our new investors, confirms the initial success and great potential of our company”, says Javier de Echevarría, CEO and co-Founder of Veritas Intercontinental. Their advanced preventive application of whole genome sequencing in healthy individuals is already a worldwide reference.” In the last two years, Veritas Intercontinental has completed the transfer of all its operations from the United States to Europe, consolidating its independent path recently finalized by the opening of a new laboratory in Spain. Veritas Intercontinental has achieved early success through its partnership agreements with some of the world’s leading health institutions, such as the Clínica Universidad de Navarra in Spain, the Centro Médico Imbanaco in Colombia, Albert Einstein Hospital – Genomika lab in Brazil, and The 90s Study in the United Kingdom. Veritas was born with the aim of making genome sequencing and clinical interpretation available to everyone as a tool to prevent diseases and improve health and quality of life.